UCL Technology Fund invests in intellectual property and spinout companies originating from University College London.
The seed round was co-led by UCL Technology Fund, Clean Growth Fund, XTX Ventures, and Dorilton
"AI computational needs are increasing by 10 times every 18 months. This leads to distributed training and inference across large numbers of xPUs. Collective data movement across the servers in the data centre becomes a bottleneck which in turn limits the training and inference completion time. This requires a fundamental shift in the co-design of next generation networked systems."
The seed round was led by UCL Technology Fund to support the development and practical application of the company technology.
"Our mission at Stanhope AI is to bridge the gap between neuroscience and artificial intelligence, creating a new generation of AI systems that can think, adapt, and decide like humans. We believe this technology will transform the capabilities of AI and robotics and make them more impactful in real-world scenarios. We trust the math and we’re delighted to have the backing of investors like UCL Technology Fund who deeply understand the science behind this technology and their support will be significant on our journey to revolutionise AI technology."
Playground Global led the Series A round to support the firm in achieving practical quantum advantage.
"For all the advances that have been made in quantum hardware, and for all quantum computing’s promise, such progress could end up being for nothing if we can’t build the applications needed to make the technology truly useful. With our record-breaking algorithms and groundbreaking techniques, we are pushing the boundaries of what is possible in this space. With support from such a renowned deep-tech visionary as Playground, we think practical quantum advantage is achievable in years, not decades."
The Series A round included backing from British Patient Capital, F-Prime Capital, and Sofinnova Partners.
"Tenpoint Therapeutics has been built on the pioneering work of its scientific founders who are recognised leaders in ocular therapies. Their vision combined with research excellence provides the best foundation to develop treatments that could be gamechangers for millions of patients worldwide. Through Future Fund: Breakthrough, we are delighted to support this truly innovative British business with the funding to take the business to the next level."
The UCL spinout secured backing from BGF and UCL Technology Fund to advance its rapid battery charging technology.
"The electrification of transport will be a big part of society’s journey towards a low carbon economy. That journey must be accomplished without delay, so it is imperative that we identify and remove the biggest barriers to EV adoption as quickly as possible. Range anxiety and long charging times are at the top of the list for attention and Gaussion’s new fast-charge technology promises to remove them"
